June 4, 2019, Medscape 

It's not often that a systemic oral therapy significantly improves overall survival (OS) in the setting of metastatic cancer. And, in the case of CDK4/6 inhibitors for breast cancer, it was looking like one might not do so, as multiple previous trials were limited to a significant improvement in progression-free survival.

Read more.